Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Nabholtz JM, et al. Among authors: von euler m. J Clin Oncol. 2000 Nov 15;18(22):3758-67. doi: 10.1200/JCO.2000.18.22.3758. J Clin Oncol. 2000. PMID: 11078488 Clinical Trial.
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M. Bonneterre J, et al. Among authors: von euler m. J Clin Oncol. 2000 Nov 15;18(22):3748-57. doi: 10.1200/JCO.2000.18.22.3748. J Clin Oncol. 2000. PMID: 11078487 Clinical Trial.
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M; Arimidex Writing Committee; Investigators Committee Members. Bonneterre J, et al. Among authors: von euler m. Cancer. 2001 Nov 1;92(9):2247-58. doi: 10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y. Cancer. 2001. PMID: 11745278 Clinical Trial.
Investigator-initiated trials of targeted oncology agents: why independent research is at risk?
Bergmann L, Berns B, Dalgleish AG, von Euler M, Hecht TT, Lappin GL, Reed N, Palmeri S, Smyth J, Embacher-Aichorn S, Zwierzina H; Biotherapy Development Association. Bergmann L, et al. Among authors: von euler m. Ann Oncol. 2010 Aug;21(8):1573-1578. doi: 10.1093/annonc/mdq018. Epub 2010 Feb 4. Ann Oncol. 2010. PMID: 20133383 Free PMC article. Review.
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.
McCabe C, Bergmann L, Bosanquet N, Ellis M, Enzmann H, von Euler M, Jönsson B, Kallen KJ, Newling D, Nüssler V, Paschen B, de Wilde R, Wilking N, Teale C, Zwierzina H; Biotherapy Development Association. McCabe C, et al. Among authors: von euler m. Ann Oncol. 2009 Mar;20(3):403-12. doi: 10.1093/annonc/mdn603. Epub 2008 Oct 14. Ann Oncol. 2009. PMID: 18854550 Free article. Review.
Restoration of conformation of mutant p53.
Green JA, Von Euler M, Abrahmsen LB. Green JA, et al. Among authors: von euler m. Ann Oncol. 2018 May 1;29(5):1325-1328. doi: 10.1093/annonc/mdy057. Ann Oncol. 2018. PMID: 29462239 Free article. No abstract available.
[Molecule based diagnosis].
Akaza H, Ichikawa T, Tsuruo T, Shimada Y, Moriwaki H, Mori M, Noguchi S, Nakamura S, Saijo N, Sone S, Isonishi S, Ohashi Y, Hinotsu S, von Euler M, Blackedge G. Akaza H, et al. Among authors: von euler m. Gan To Kagaku Ryoho. 2004 Jan;31(1):125-33. Gan To Kagaku Ryoho. 2004. PMID: 14750337 Review. Japanese.
141 results